News >

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

Jason Harris
Published: Thursday, Sep 07, 2017

multiple myeloma
The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Paris-based biopharmaceutical company Cellectis is developing UCART123 as a treatment for BPDCN and AML. The company said in a press release that it is working with the FDA to resume the trials with an amended protocol, including a reduced dose of UCART123 cells.
1. FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA® (pembrolizumab) in Patients with Multiple Myeloma. https://www.fda.gov/Drugs/DrugSafety/ucm574305.htm. Accessed August 31, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x